AC Immune posts positive data for Parkinson's immunotherapy, shares rise

AC Immune announced encouraging new data for its Parkinson's disease immunotherapy candidate, leading to a double-digit increase in its share price. The company now plans to engage with regulators to potentially accelerate the timeline for an approval filing based on the positive results.